Ipca Laboratories Limited

Dharmendra Singh

Ashok Kumar

Ganesh Devidas Mahale

Pramilkumar Mathur

Swapnali Hemant Patil

Uttamrao Arjunrao Sawant

Nellithanath Thankachen Byju

Gaurav Sahal

Suneel Yeshwant Dike

Vitthal Suryabhan Buchude

Ramsingh Gajendrasingh Thakur

Shankar Deepak Panmand

Navinchandra Darpan Pandya

Atul Jadhav

Mahesh Kharade

Ragnesh Kumar Rana

Swapnil Shreekant Kore

Brajesh Sharma

Pramil Kumar Mathur

Ragneshkumar Rana

Balasaheb Ganpat Jadhav

Vitthal Syryabhan Buchude

Durga Prasad Samantaray

Rakesh Kumar Bhasin

Thankachen Byju Nellithanath

The present invention relates to a novel pharmaceutical composition having enhanced bioavailability through improved aqueous dissolution of poorly water soluble drugs, and to a method for preparing it. The invention more particularly relates to an oral pharmaceutical composition containing active ingredients of poor aqueous solubility, more specifically, antiparasitic and antipneumocystic drug Atovaquone alone or in combination with Proguanil.

Pharmaceutical composition

Disclosed are complexes of an antipneumocystic compound and an antimalarial compound, processes for their preparation, pharmaceutical compositions and methods of using said complexes or compositions for the treatment and/or prophylaxis of parasitic infections.

Complex for treatment and/or prophylaxis of parasitic infections

Disclosed herein is an industrial preparation of Quetiapine by the reaction of 11-piperazinyldibenzo[b,f][1,4]-thiazepine or its salt with 2-(2-chloroethoxy)ethanol in presence of an organic or inorganic base under neat or aqueous condition to form 11-[4-{2-(2-hydroxyethoxy)ethyl}-1-piperazinyl]dibenzo[b,f]-[1,4]thiazepine. The quetiapine free base obtained is further converted to its hemi-fumarate salt.

Industrial preparation of 11-[4-{2-(2-hydroxyethoxy) ethyl}-1-piperazinyl] dibenzo [b,f]-[1,4]thiazepine

Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as 'Form IPCA-ATO,' and the preparation thereof.

Process for preparation of atovaquone and novel intermediates thereof

The present invention relates to a process for preparation of isotretinoin and more specifically, to a purification process for obtaining highly pure isotretinoin that is useful as a keratolytic agent, particularly useful for the treatment of acne. The process involves treating isotretinoin containing metal contamination and/or other impurities with a base in a suitable solvent to form a solution of isotretinoin, followed by adsorption, precipiation, and filtration or centrifugation.

Process for preparation of highly pure isotretinoin

A one-pot industrial process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one of Formula-(I) from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one of Formula-(IV) involves reaction of Formula (IV) with HNRRsalt and paraformaldehyde, where R,Rare independently alkyl groups or together forms a cyclic alkyl group, in a solvent system of acetic acid and hydrocarbon solvent to form a crude mixture of intermediate compounds of Formula (III) and (VIII), which is converted to ondansetron (Formula (I)) without isolation by reaction with 2methyimidazole in a suitable solvent system in the same pot.

One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O

The present invention discloses selective and complete reduction of pyridine ring in a biaryl system comprising &#x221d;-substituted or non-substituted benzene ring and relates more specifically, not exclusively, for the manufacture of methylphenidate, which is used for treatment of Attention Deficit Hyperactive Disorder (ADHD) and also acts as central nervous system stimulant, by using palladium/C in a solvent such as C1-C4 alcohols in presence of molar quantities of organic and/or inorganic acids.

Manufacturing process for methyl phenidate and intermediates thereof

Growing community of inventors

Maharashtra, India

Dharmendra Singh